LakeShore Biopharma Co., Ltd. (Nasdaq: LSB), a global biopharmaceutical company focused on developing and manufacturing vaccines and therapeutic biologics for infectious diseases and cancer, released its unaudited financial results for the first half of fiscal year 2025, ending September 30, 2024.
CEO Xu Wang expressed confidence in the company’s performance, citing the remarkable financial results achieved under the leadership of the newly appointed management team. “We are thrilled with our performance in the first half of FY2025, especially in light of the challenging macroeconomic conditions in China, intensified competition, and recent disruptions caused by former Chairman Yi Zhang. For the first time since 2013, we have reported a net income of RMB 20.6 million,” Wang said. “Furthermore, our revenue growth during this period significantly outpaced that of many vaccine companies operating in China.”
Wang attributed the company’s financial turnaround to a series of successful strategies designed to enhance operational efficiency, reduce costs, and improve profitability. These included organizational restructuring, better resource allocation, stronger internal controls, and more effective cash flow management.
Looking ahead, Wang reaffirmed the company’s commitment to its growth strategy. “We are focused on maximizing value from our current product portfolio while driving new business opportunities. This will position us for continued financial success in FY2025 and beyond, ensuring the long-term value for our shareholders.”
Related topics
